Health insurer Anthem has reached a deal that makes Gilead Sciences’ Harvoni the primary treatment for patients with hepatitis C, following close on the heels of hep C drug announcements by CVS Health and Express Scripts.
Health insurer Anthem has reached a deal that makes Gilead Sciences’ Harvoni the primary treatment for patients with hepatitis C, according to Bloomberg News.
Additionally, Prime Therapeutics finalized deals with both Gilead and AbbVie to co-prefer both Harvoni and Viekira Pak to treat hepatitis C genotype 1. Prime said that it “carefully evaluated all options,” and determined that both Harvoni and Viekira proved to be the lowest cost option for its clients.
These moves follow close on the heels of Express Scripts’ decision to make AbbVie’s Viekira Pak the exclusive hepatitis C treatment in its formulary, as well as CVS Health’s announcement that Gilead’s Harvoni and Sovaldi will be the exclusive option for patients on its commercial drug list, as well as those on Medicare Part D and Medicaid.
“Gilead's CVS/Caremark agreement is broader than Express Script's agreement with Express Scripts, offering the standard commercial, Medicare Part D, and Managed Medicaid formularies,” says F. Randy Vogenberg, is a partner at Access Market Intelligence, and principal, Institute for Integrated Healthcare, Greenville, S.C.
More than 3 million people in the United States are believed to be infected with hepatitis C.
“Even though Insurers are beginning to take sides, they are not always aligning with their PBM if they can cut a better deal on their own terms,” says John Santilli of Access Market Intelligence, which provides market intelligence to the pharmaceutical and healthcare industries.
“Anthem represents more than 10% of Express Scripts' patients but was able to negotiate favorable pricing from Gilead on its own,” Santilli explains.
Gilead has been scrutinized for the high cost of Harvoni ($94,500 for 12 weeks of treatment, or $1,125 per daily tablet) and Sovaldi ($1,000 per pill).
A Conversation With Greg Baker, RPh, CEO of AffirmedRx
March 31st 2024Greg Baker, CEO of AffirmedRx, describes his early career, shares some of his critical opinions about the pharmacy benefit management (PBM) industry and how, in his view, his company is offering a better alternative.
Read More
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Upended: Can PBM Transparency Succeed?
March 6th 2024Simmering tensions in the pharmacy benefit management (PBM) industry have turned into fault lines. The PBMs challenging the "big three" have formed a trade association. Purchaser coalitions want change. The head of the industry's trade group says inherent marketplace friction has spilled over into political friction.
Read More
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
In this second part of a video series, AMCP CEO Susan Cantrell addressed the impact of high prescription drug prices on underserved communities, highlighting disparities in access caused by the pandemic's effects on minority populations. On the industry blame debate, she urged collaborative solutions, mentioning AMCP's engagement with diverse stakeholders to find comprehensive, patient-centric solutions and advocate for policy changes like the MVP Act to address rising costs and access challenges.
Read More